- Home
- NYXH vs RGNX Comparison
NYXH vs RGNX Comparison
Compare NYXH & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NYXH
- RGNX
- Stock Information
- Founded
- NYXH 2009
- RGNX 2008
- Country
- NYXH Belgium
- RGNX United States
- Employees
- NYXH N/A
- RGNX N/A
- Industry
- NYXH Medical/Dental Instruments
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NYXH Health Care
- RGNX Health Care
- Exchange
- NYXH Nasdaq
- RGNX Nasdaq
- Market Cap
- NYXH 394.1M
- RGNX 387.0M
- IPO Year
- NYXH 2021
- RGNX 2015
- Fundamental
- Price
- NYXH $6.50
- RGNX $7.05
- Analyst Decision
- NYXH Strong Buy
- RGNX Strong Buy
- Analyst Count
- NYXH 4
- RGNX 9
- Target Price
- NYXH $14.75
- RGNX $32.89
- AVG Volume (30 Days)
- NYXH 86.3K
- RGNX 976.0K
- Earning Date
- NYXH 05-13-2025
- RGNX 05-07-2025
- Dividend Yield
- NYXH N/A
- RGNX N/A
- EPS Growth
- NYXH N/A
- RGNX N/A
- EPS
- NYXH N/A
- RGNX N/A
- Revenue
- NYXH $4,680,609.00
- RGNX $83,328,000.00
- Revenue This Year
- NYXH $504.18
- RGNX $285.14
- Revenue Next Year
- NYXH $149.52
- RGNX N/A
- P/E Ratio
- NYXH N/A
- RGNX N/A
- Revenue Growth
- NYXH 3.98
- RGNX N/A
- 52 Week Low
- NYXH $6.30
- RGNX $5.62
- 52 Week High
- NYXH $13.50
- RGNX $20.77
- Technical
- Relative Strength Index (RSI)
- NYXH 21.44
- RGNX 45.61
- Support Level
- NYXH $10.26
- RGNX $7.96
- Resistance Level
- NYXH $11.87
- RGNX $8.35
- Average True Range (ATR)
- NYXH 0.75
- RGNX 0.66
- MACD
- NYXH -0.48
- RGNX -0.08
- Stochastic Oscillator
- NYXH 3.59
- RGNX 22.99
About NYXH Nyxoah SA
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. Nyxoah's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.